Background: Mutations in the CHEK2 gene confer a moderately increased breast cancer risk. The risk for female carriers of the CHEK2*1100delC mutation is twofold increased. Breast cancer risk for carrier women is higher in a familial breast cancer setting which is due to coinheritance of additional genetic risk factors. This study investigated the occurrence of homozygosity for the CHEK2*1100delC allele among familial breast cancer cases and the associated breast cancer risk. Methods and results: Homozygosity for the CHEK2*1100delC allele was identified in 8/2554 Dutch independent familial non-BRCA1/2 breast cancer cases. The genotype relative risk for breast cancer of homozygous and heterozygous familial breast cancer cases was 101.34 (95% CI 4.47 to 121 000) and 4.04 (95% CI 0.88 to 21.0), respectively. Female homozygotes appeared to have a greater than twofold increased breast cancer risk compared to familial CHEK2*1100delC heterozygotes (p=0.044). These results and the occurrence of multiple primary tumours in 7/10 homozygotes indicate a high cancer risk in homozygous women from non-BRCA1/2 families. Conclusions: Intensive breast surveillance is therefore justified in these homozygous women. It is concluded that diagnostic testing for biallelic mutations in CHEK2 is indicated in non-BRCA1/2 breast cancer families, especially in populations with a relatively high prevalence of deleterious mutations in CHEK2.

dx.doi.org/10.1136/jmedgenet-2011-100380, hdl.handle.net/1765/65759
Journal of Medical Genetics
Erasmus MC: University Medical Center Rotterdam

Adank, M.A, Jonker, M.A, Kluijt, I, van Mil, S.E, Oldenburg, R.A, Mooi, W.J, … Waisfisz, Q. (2011). CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. Journal of Medical Genetics, 48(12), 860–863. doi:10.1136/jmedgenet-2011-100380